AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections
12. Januar 2021 08:30 ET
|
AzurRx BioPharma, Inc.
Patent allowed by the USPTO that includes claims for niclosamide as a treatment for COVID-19 GI infectionsCOVID-19 GI infections are a significant unmet clinical need; AzurRx estimates potential U.S....